FDA发布药品与生物制品报告量技术符合性指南最终版
Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide
FDA发布《药品与生物制品报告量技术符合性指南》最终版，协助药品生产企业注册人按FD&C法案510(j)(3)提交报告。该指南说明首次使用者如何访问FDA的CDER NextGen门户提交报告、通过门户提交的不同方法以及报告应包含的数据要素，并补充2021年10月的同名草案指南。文件编号为FDA-2021-D-1031，由CDER、CBER和CVM发布。
该指南补充 2021 年 10 月同名草案，说明通过 CDER NextGen 门户提交报告的操作方法及所需数据要素。
GUIDANCE DOCUMENT
Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide Guidance for Industry February 2024
Final Level 2 Guidance
- Docket Number:
- FDA-2021-D-1031
- Issued by:
-
Guidance Issuing Office
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research
Center for Veterinary Medicine
FDA is issuing this Technical Conformance Guide (guide) to assist registrants of drug establishments (or their authorized agents) in submitting reports on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3112(e) of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). This guide supplements the draft guidance for industry Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act (October 2021). The guide describes 1) how first-time users can access FDA’s CDER NextGen Portal (the portal) to submit these reports, 2) the different methods for submitting the reports through the portal, and 3) the data elements to be included in the reports.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2021-D-1031.
来源：FDA Pharmaceutical Quality Documents · fda.gov